Bayer's Zieler On Building An Asian Alliance Trove
Bayer AG is experimenting with both traditional and new collaboration models as part of its innovation strategy and the German multinational appears keen to build on early gains in scientific hotspots in Asia. Claus Zieler, senior vice-president and head of commercial operations, Bayer pharmaceuticals division Asia-Pacific, tells Scrip how the company is faring in the region.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.